Nursing Perspectives on Managing Toxicities With ADCs in Metastatic Gastric and Breast Cancers

Sap Partners | Cancer Centers | <b>UCSF Helen Diller Family Comprehensive Cancer Center</b>

In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.

In this episode of The Vitals, a panel of oncology nurses and nurse practitioners with backgrounds in gastric and breast cancer unpack adverse event (AE) management with HER2-directed anti-body drug conjugates (ADCs).

Sarah Donahue, MPH, NP, AOCNP, of the University of California San Francisco Health recently moderated a discussion with Jamie Carroll, APRN, CNP, MSN, of the Mayo Clinical in Rochester Minnesota; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN, of the Winship Cancer Institute with Emory University; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN of the Abramson Cancer Center with the University of Pennsylvania. The Peer Exchange program was structured to highlight real-world scenarios to put best nursing practices into context when using approved ADCs in clinic.

Following a case study presented by Gillespie on a woman with metastatic gastric cancer who developed neutropenia while receiving fam-trastuzumab deruxtecan-nxki (Enhertu), the panel discuss the other potential AEs associated with this treatment—including neuropathy, nausea, and interstitial lung disease. They compare the rate of incidences for these AEs between gastric and breast cancers, pose questions regarding the value of interdisciplinary collaboration with pulmonary teams, and pitch questions regarding agent suitability for patients with pre-existing comorbidities.

Basing their conversation around published clinical trial data and experience from their personal practice, they discuss how to best manage these events, wrapping up with clinical pearls for all oncology nurses who care for patients receiving an ADC for metastatic disease.

If you liked today’s episode of The Vitals, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms, to get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to The Vitals. Be sure to never miss a beat with Oncology Nursing News®.

This episode of The Vitals was sponsored in part by Daiichi Sankyo. Content independently developed by Oncology Nursing News®.